Clinical trials for GLP-1 agonists have found that nausea occurs in 15% to 30% of patients, diarrhea in 10-15%, and vomiting in 5-10% (usually as a result of the nausea)
Getting started Check your eligibility it takes about a minute and there is no obligation
Semaglutide reduces markers of inflammation in the body, contributing to better cardiovascular health
Matsuo K, Mizoue T, Tanaka K, Tsuji I, Sugawara Y, Sasazuki S, Nagata C, Tamakoshi A, Wakai K, Inoue M, Tsugane S (2012) Association between body mass index and the colorectal cancer risk in Japan: pooled analysis of population-based cohort studies in Japan
Recent advancements in therapeutic strategies, including bile composition modulation, microbiome interventions, and nanoparticle-based drug delivery, present promising approaches for gallstone prevention and treatment
Am.J Kidney Dis 1999;34(4):678-687